Summary & Overview
Cardiac Pacemaker Revision Except Device Replacement without CC/MCC: Inpatient Reimbursement Overview
DRG 262 encompasses inpatient admissions for cardiac pacemaker revision procedures excluding pulse generator replacements when no Major Complication or Comorbidity and no Complication or Comorbidity are present, covering lead and pocket revisions. This Diagnosis-Related Group is important for inpatient reimbursement because it defines the payment grouping used by the Centers for Medicare & Medicaid Services for these procedures and reflects expected resource intensity.
DRG 262 Overview
DRG 262 covers inpatient hospital admissions for cardiac pacemaker revision procedures except device replacement when no Major Complication or Comorbidity and no Complication or Comorbidity are present. It includes surgical adjustments, lead revisions, and related pocket revisions without replacement of the pulse generator and without significant additional diagnoses. This Diagnosis-Related Group matters for Centers for Medicare & Medicaid Services payment because it groups similar resource use and drives prospective payment for these specific inpatient encounters. Accurate coding and documentation determine assignment to this Diagnosis-Related Group and thus the associated Medicare reimbursement.
Clinical Trials
- Studies evaluating procedural techniques and device programming strategies for pacemaker lead revision, focusing on intraoperative approaches (e.g., transvenous lead extraction versus lead repositioning) and perioperative management protocols. These trials enroll patients admitted for pacemaker revision procedures without major complications, assessing short-term procedural success, complication rates like lead dislodgement or infection, and hospital resource use. Results inform surgeons and electrophysiologists on safest, most efficient revision techniques and help payers understand procedure-related utilization and cost drivers for this DRG.
- Comparative effectiveness trials examining management pathways for patients with pacemaker malfunction or lead issues who have varying comorbid burdens, such as trials comparing expedited revision during the same admission versus staged outpatient follow-up and delayed intervention. Populations include older adults with multiple chronic conditions who present with symptomatic bradyarrhythmias or device alerts but do not have major complications; outcomes include readmissions, symptom control, and total episode-of-care cost. Findings help clinicians stratify which patients benefit from immediate inpatient revision versus conservative or delayed strategies, aiding discharge planning and payer decisions about appropriate inpatient utilization.
- Post-discharge observational cohort and quality-of-life studies assessing long-term outcomes after pacemaker revision, such as device longevity, recurrent lead problems, infection rates, functional status, and health-related quality of life over months to years. These studies track patients discharged after uncomplicated revision procedures to identify predictors of late complications, outpatient follow-up needs, and patterns of healthcare utilization including emergency visits and rehospitalizations. Data are valuable for providers optimizing follow-up schedules and for payers modeling long-term cost-effectiveness and readmission risk associated with index inpatient care captured under this DRG.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.